| The National Paediatric Diabetes Audit assess the care received by children and young people with diabetes in all Paediatric Diabetes Units (PDUs) across England and Wales (HQIP)
Short-acting exenatide does not seem to have a future as a standard add-on treatment to insulin therapy in type 1 diabetes (The Lancet Diabetes & Endocrinology)
The T1DCI is a powerful metric to evaluate the ability of our diabetes program to standardize, quantify, and monitor delivery of optimal diabetes care to children with T1D, and to drive our program towards zero missed opportunities for quality care delivery (Pediatric Diabetes)
| 
